Soleus Capital Management L.P. Cuts Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Soleus Capital Management L.P. reduced its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 23.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 205,294 shares of the specialty pharmaceutical company's stock after selling 63,706 shares during the period. Soleus Capital Management L.P. owned 0.98% of ANI Pharmaceuticals worth $11,349,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Exchange Traded Concepts LLC grew its stake in ANI Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company's stock worth $684,000 after acquiring an additional 310 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in ANI Pharmaceuticals by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock worth $582,000 after acquiring an additional 364 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock worth $246,000 after acquiring an additional 412 shares in the last quarter. Natixis Advisors LLC grew its stake in ANI Pharmaceuticals by 2.3% in the 4th quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company's stock worth $1,028,000 after acquiring an additional 417 shares in the last quarter. Finally, US Bancorp DE grew its stake in ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after acquiring an additional 531 shares in the last quarter. 76.05% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 881 shares of ANI Pharmaceuticals stock in a transaction on Thursday, May 15th. The shares were sold at an average price of $60.07, for a total value of $52,921.67. Following the completion of the transaction, the senior vice president now owns 89,897 shares of the company's stock, valued at approximately $5,400,112.79. The trade was a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christopher Mutz sold 4,000 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, May 14th. The shares were sold at an average price of $60.45, for a total transaction of $241,800.00. Following the completion of the transaction, the insider now directly owns 107,317 shares of the company's stock, valued at $6,487,312.65. The trade was a 3.59% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,681 shares of company stock valued at $408,498 over the last 90 days. Insiders own 11.10% of the company's stock.

ANI Pharmaceuticals Stock Performance

Shares of ANI Pharmaceuticals stock traded up $0.52 during trading on Friday, hitting $57.79. 244,161 shares of the company's stock were exchanged, compared to its average volume of 302,086. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74. The business has a 50-day simple moving average of $66.49 and a 200-day simple moving average of $60.80. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $77.00. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -105.07 and a beta of 0.56.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its earnings results on Friday, May 9th. The specialty pharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.37 by $0.33. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The firm had revenue of $197.12 million during the quarter, compared to analysts' expectations of $179.75 million. During the same quarter last year, the company posted $0.82 earnings per share. The firm's revenue was up 43.4% compared to the same quarter last year. On average, research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Guggenheim reissued a "buy" rating and set a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. HC Wainwright reissued a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, March 17th. Wall Street Zen lowered shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Thursday, April 24th. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 price objective on the stock. Finally, Truist Financial lifted their price objective on shares of ANI Pharmaceuticals from $62.00 to $65.00 and gave the company a "hold" rating in a report on Monday, April 21st. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, ANI Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $80.13.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.